Latest News

Higher Doses of Oral Prednisone Delays Relapse Onset in MOG-Antibody Disease
Higher Doses of Oral Prednisone Delays Relapse Onset in MOG-Antibody Disease

June 22nd 2024

Patients treated with at least 12.5 mg/day of oral prednisone for at least 3 months had an 88% reduction in the risk of relapse compared with those who did not receive this regimen.

FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory Demyelinating Polyneuropathy
FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory Demyelinating Polyneuropathy

June 21st 2024

NeurologyLive® Friday 5 — June 21, 2024
NeurologyLive® Friday 5 — June 21, 2024

June 21st 2024

Neal K. Shah  (Credit: CareYaya Health Technologies)
A Breath of Fresh Air: Innovative Solutions for Addressing Sleep Apnea and Cognitive Decline in Older Adults

June 21st 2024

Jerry Mendell, MD
FDA Grants Traditional Approval to Elevidys Gene Therapy for Ambulatory DMD, Accelerated Approval for Nonambulatory Patients

June 20th 2024

Coverage of SLEEP 2024

Get the latest data and clinical news updates, as well as interviews with experts, straight from the conference floor of SLEEP 2024.

SLEEP 2024

Conference Coverage

View All
Role of Sleep Chronotype, Circadian Rhythm in Neurocognitive Health: Ashley Curtis, PhD
Role of Sleep Chronotype, Circadian Rhythm in Neurocognitive Health: Ashley Curtis, PhD

June 22nd 2024

Understanding the Importance of Maternal-Fetal Circadian Synchrony
Understanding the Importance of Maternal-Fetal Circadian Synchrony

June 20th 2024

Treatment Decisions With Stable Multiple Sclerosis
Treatment Decisions With Stable Multiple Sclerosis

June 19th 2024

Switching From S1P-Modulating Therapies to Other DMTs
Switching From S1P-Modulating Therapies to Other DMTs

June 19th 2024

Video Series
Video Interviews
Podcasts

Most Recent

© 2024 MJH Life Sciences

All rights reserved.